Edition:
United States

Teva Pharmaceutical Industries Ltd (TEVA.N)

TEVA.N on New York Stock Exchange

6.41USD
16 Aug 2019
Change (% chg)

$0.25 (+4.06%)
Prev Close
$6.16
Open
$6.19
Day's High
$6.43
Day's Low
$6.08
Volume
3,172,619
Avg. Vol
3,664,405
52-wk High
$25.96
52-wk Low
$6.07

About

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic... (more)

Overall

Beta: 1.61
Market Cap(Mil.): $8,611.66
Shares Outstanding(Mil.): 1,092.46
Dividend: 0.09
Yield (%): --

Financials

  TEVA.N Industry Sector
P/E (TTM): -- 29.73 33.85
EPS (TTM): -3.42 -- --
ROI: -7.51 13.04 12.69
ROE: -23.76 14.12 17.13

Teva settles multibillion-dollar drug kickback case ahead of trial

Teva Pharmaceutical Industries Ltd has agreed on the eve of trial to settle a multibillion-dollar whistleblower lawsuit alleging it paid doctors kickbacks to prescribe its Parkinson's disease drug Azilect and multiple sclerosis treatment Copaxone.

Aug 15 2019

Judge certifies Niaspan 'pay-for-delay' class action against AbbVie, Teva

A federal judge on Wednesday certified a class of drug purchasers suing AbbVie Inc and Teva Pharmaceutical Industries Ltd over an alleged anticompetitive agreement that delayed the release of a generic version of the cholesterol drug Niaspan.

Aug 14 2019

U.S. lawmakers push Mylan, Teva over drug pricing probe

WASHINGTON The head of the U.S. House of Representative's oversight panel on Wednesday called on three drugmakers to turn over documents as part of an ongoing congressional review over generic drug price increases and accused the companies of "apparent efforts to stonewall" the probe.

Aug 14 2019

UPDATE 3-U.S. lawmakers push Mylan, Teva over drug pricing probe

WASHINGTON, Aug 14 The head of the U.S. House of Representative's oversight panel on Wednesday called on three drugmakers to turn over documents as part of an ongoing congressional review over generic drug price increases and accused the companies of "apparent efforts to stonewall" the probe.

Aug 14 2019

U.S. lawmakers push Mylan, Teva over drug pricing probe -statement

WASHINGTON, Aug 14 The head of the U.S. House of Representative's oversight panel on Wednesday called on three drugmakers to turn over documents as part of an ongoing congressional review over generic drug price increases and accused the companies of "apparent efforts to stonewall" the probe.

Aug 14 2019

Israel's Teva Pharm profit falls less than expected, CFO to leave

TEL AVIV Teva Pharmaceutical Industries reported a smaller-than-expected drop in second-quarter profit on Wednesday and said its chief financial officer was leaving the company.

Aug 07 2019

UPDATE 2-Israel's Teva Pharm profit falls less than expected, CFO to leave

* Migraine drug Ajovy Q2 sales reach $23 mln (Adds CEO comments from conference call, interview)

Aug 07 2019

Israel's Teva Pharm Q2 profit falls less than expected

TEL AVIV, Aug 7 Israel-based Teva Pharmaceutical Industries reported a smaller-than-expected drop in second-quarter profit on Wednesday and reaffirmed its full year outlook.

Aug 07 2019

Newer drugs help Eli Lilly top Wall Street quarterly profit estimate

Eli Lilly and Co reported a second-quarter profit that topped Wall Street estimates and raised its 2019 earnings forecast on Tuesday, as higher demand for newer drugs offset increased discounts for the U.S. Medicare program and sales declines of medicines that lost patent protection.

Jul 30 2019

UPDATE 3-Newer drugs help Eli Lilly top Wall Street quarterly profit estimate

July 30 Eli Lilly and Co reported a second-quarter profit that topped Wall Street estimates and raised its 2019 earnings forecast on Tuesday, as higher demand for newer drugs offset increased discounts for the U.S. Medicare program and sales declines of medicines that lost patent protection.

Jul 30 2019
Reuters.com is improving our Quote page. Click here to take a look and let us know what you think.

Earnings vs. Estimates